Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum T-Bird Pharma Inc. V.TPI

TSXV:TPI - Post Discussion

T-Bird Pharma Inc. > RTB and MMPR Comparables
View:
Post by jimrockford on Oct 15, 2014 10:06am

RTB and MMPR Comparables

Matica - $3.8 million mkt cap - has a Right-to-Build and Health Can site visit on Oct 26th (the halt should be off next week)
Prescient - Over $100 mil mkt cap- has a Right-to-Build
Supreme Pharmaceuticals - $24.3 million mkt cap - has a Right-to-Build
Affinor - $24.5 million mkt cap - waiting for Health Canada licenses and approvals
Abattis - $17.8 million mkt cap - awaiting the Right-to-Build
Organigram - $72.2 million mkt cap - MMPR
Bedrocan - $45.9 million - mkt cap - MMPR - importing cannabis - now building a facility in Canada
Mettrum - $55.6 million mkt cap - MMPR
Tweed - $80.2 million mkt cap - MMPR
T-Bird Pharma - $24.5 million mkt cap - has an MMPR - but very small
Be the first to comment on this post
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities